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ABSTRACT
In the combined antiretroviral therapy era, HIV-infected patients remain a vulnerable population for
the onset of bloodstream infections (BSI). Worldwide, nontyphoid salmonellae, Streptococcus
pneumoniae, Escherichia coli, Staphylococcus aureus and coagulase negative staphylococci are the
most important pathogens. Intravenous catheter associated infection, skin-soft tissue infection and
endocarditis are associated with Gram-positive bacteremia. Among the Gram-negative,
nontyphoidal Salmonella have been previously correlated to sepsis. Other causes of BSI in HIV-
infected patients are mycobacteria and fungi. Mycobacteria constitute a major cause of BSI in
limited resource countries. Fungal BSI are not frequent and among them Cryptococcus neoformans is
the most common life-threatening infection. The degree of immunosuppression remains the key
prognostic factor leading to the development of BSI.
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Introduction
Despite the dramatic reduction of AIDS-related deaths and
opportunistic infection rate after the introduction of com-
bined antiretroviral therapy (cART), infection with the
human immunodeﬁciency virus (HIV) remains a cause of
increased risk of bloodstream infection (BSI).1-4 HIV-
infected patients remain a “fragile” population, even after
achieving an acceptable immunological status, as their mor-
tality decreases to levels comparable to the general popula-
tion only after 6–10 y of immune-recovery and HIV-RNA
suppression.5,6 Many factors appear to predispose HIV-
infected patients to invasive bacterial and fungal infections;
in particular, altered cell-mediated immunity, B-cell dys-
function with consequent lack of serum opsonins as well as
qualitative and quantitative deﬁcits of neutrophils.7 HIV-
infected patients are not fully immune until the CD4CT
(CD4) cell count increases to >750 cells/mL.8 In HIV-
infected patients with CD4 cell count>500 cells/mL the risk
of infectious diseases and even of AIDS-deﬁning infections
(e.g. recurrent pneumonia and extra-pulmonary tuberculo-
sis) are higher compared to the general population.8 The
recent START-INSIGHT trial demonstrated that the CD4
cell count is crucial to deﬁne a patient’s immunological sta-
tus and to establish the timing of cART initiation. Indeed,
patients who started cART early had a signiﬁcantly lower
probability of AIDS and non-AIDS events (e.g., bacterial
infections), even when their baseline CD4 cell counts was
>500 cells/mL.9
Two main factors inﬂuence the epidemiology of BSI in
HIV-infected patients; the availability of cART, which has
determined a reduction of incidence and a change of clini-
cal characteristics of BSI in industrialized countries; 10
and the geographic distribution of some pathogens.3 BSI
are associated with increasedmortality rate, length of hos-
pital stay and intensive care unit (ICU) admission rate.11
BSI are now a more frequent cause of ICU admission
than Pneumocystis jiroveci pneumonia in HIV-infected
patients.12,13 Nontyphoid salmonella, Streptococcus pneu-
moniae, Escherichia coli and Staphylococcus aureus are
the most important pathogens of BSI. Fungal and myco-
bacterial infections are less frequent but can have consid-
erable clinical and economic impact. Among the
pathogens responsible for BSI,Mycobacteria spp., Crypto-
coccus neoformans and recurrent nontyphoid salmonella
constitute AIDS-deﬁning conditions.14
This review describes the main characteristics of BSI in
HIV-infected patients, focusing on the etiology, risk factors
and outcome. A major scientiﬁc database15 was searched,
with the search string (HIV or AIDS) and (bloodstream
infectionOR sepsis OR fungemia OR bacteremia).
Bacterial BSI
The type and incidence of bacterial BSI in HIV-infected
patients depend on the historical period (pre-cART
or cART era), the geographic area (developed or
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resource-limited countries) and the clinical setting (com-
munity or hospital). Table 1 summarizes the frequency
and the principal etiologies of bacterial BSI.
Gram-positive bacteria
Streptococcus pneumoniae
Invasive pneumococcal disease (IPD) is an important
cause of bacteremia in HIV-infected patients throughout
the world. Incidence rates of IPD can be up to 100-fold
higher in HIV-infected individuals compared to a non-
HIV population withmore frequent recurring invasive dis-
ease.16,17 The relative risk of IPD in HIV-infected patients
was estimated to be 24.4 (95% conﬁdence interval, 23.7–
25.1) in a recent study.18 The main risk factors for IPD in
the current study were male gender, intravenous drug use,
smoking, detectable HIV-RNA and low CD4 cell count.18
By contrast, the use of cART and a pneumococcal conju-
gate vaccine have been associated with protection.18,19
The mortality rate observed in HIV-infected patients
with pneumococcal bacteremia in the pre-cART era was
lower compared to the non–HIV-infected population.
This lower mortality rate might be related to several fac-
tors, including younger age, lower prevalence of associ-
ated comorbidities and decreased inﬂammatory
response, leading to a lower incidence of septic
shock.13,20,21 Neither the incidence of BSI sustained by S.
pneumoniae in the cART era, nor the mortality rate,
decreased signiﬁcantly.19 The most important factors
related to high mortality rate remain low CD4 cell count
and the severity of pneumococcal disease (e.g. intensive
care unit admission and sepsis).19,22 In the cART era,
however, HIV-infected patients are aging and this consti-
tutes an independent risk factor for IPD.18 Moreover, the
advanced age of these patients implies an increasing inci-
dence of comorbidities, including kidney diseases, diabe-
tes and cardiovascular disease, which are well-known
risk factors for pneumococcal infection in the general
population.18,19,21,23–25 The lack of improvement in the
mortality rate with the introduction of cART underlines
the need for an effective preventive vaccination strategy
but data on the 23-valent pneumococcal vaccine are
scarce.14 The vaccine antibody response appears to be
related to the CD4 cell count, with a lower response rate
at a CD4 count < 200 cells/mL.26 A multicenter case-
control study showed a reduction of IPD ratio only in
patients who received vaccination when their CD4 cell
count was >500 cells/mL.27 Conversely, a study in
Uganda when cART was not widely available demon-
strated an unexpected increase of IPD in patients vacci-
nated with the 23-valent vaccine.28
Staphylococcus aureus
S. aureus infections occurs widely in Asia, Europe and
the United States, but causes few cases of BSI in
Africa.4,10,11,29,30–35 Intravenous catheter, skin-soft tissue
infection and endocarditis are signiﬁcantly associated
with Gram-positive BSI.34 S. aureus epidemiology is
inﬂuenced by the historical era; S. aureus was the most
important pathogen of BSI in a case-control study using
all cases of community-acquired BSI identiﬁed prospec-
tively in US in the pre-cART era.30 S. aureus was the
Table 1. Frequencies of causative agents of bloodstream infections and characteristics and outcomes of patients according to the
literature.
Setting of
transmission %
Mean number of CD4C
(% of patients)
Causative Agent
Mean frequence
% (range) Community Nosocomial Any <200
Outcome (mean
crude mortality %) References
Bacteria
S. aureus 12 (2-28) 67 33 N.A. N.A. 12 11,32–35,42,54
CONS 7 (0-26) 59 41 N.A. N.A. 10 11,32–34,41,42,54
S. pneumoniae 13 (0-43) 77 23 41 59 9 4,11,19,24,25,32–35,41,42,54,57,58
NTS 15 (0-46) 80 20 30 70 34 4,14,32–35,42,49,50,53,54,57,58
E.coli 8 (0- 31) 65 35 N.A. N.A. 15 10,32–35,42,54,57
P.aeruginosa 6 (0-30) 50 50 N.A. N.A. 32 10,33–35,42,54
Others 24 (10-60)
Total Bacteria 70 (16-100) 20 4,10,11,13,32–34,42,54,57
Mycobcateria
M. tuberculosis 17 (0-54) 100 0 0 100 48 4,34,42,54,57,58,60
NTM 6 (0-17) 100 0 0 100 34,42,54,57,58
Total Mycobacteria 20 (0-63) 48 4,34,42,54,57,58,60
Fungi
Criptpcoccus spp 5 (0-21) 89 11 N.A. N.A. 26 4,33,34,42,54,64
Candida spp 1 (0-3) 23 77 26 84 41 33,34,54,64,69,70
Total fungi 10 (0-44) 35 4,33,34,42,54,57,64,69,70
Total 78 22 5 95 30 (12-68) 4,10,11,13,31–35,41,42,54
Note. CONS: coagulase negative staphylococci; NTS: non typhoidal salmonella; NTM: non tubercular mycobacteria; N.A.: not available.
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principal nosocomial BSI pathogen in a Center for Dis-
eases Control multicenter study in which it accounted
for 35% of all etiologies.36 Data for the cART era are con-
troversial. In a prospective study in US, S. aureus was the
third most frequent isolate after E. coli and S. pneumo-
niae,11 while in a single-hospital study in Spain reporting
67 episodes of Gram-positive BSI (36% of total BSI),
S. aureus (10.7%) and coagulase-negative staphylococci
(8.6%) were the 2 most frequent pathogens.34 Deﬁnitive
positioning is not possible, owing to the paucity of stud-
ies available on this topic.
Methicillin-resistant staphylococcus aureus
Among people living with HIV, the transmission of com-
munity-acquired methicillin-resistant S. aureus (CA-
MRSA) is an emerging epidemic, with higher prevalence
in healthcare settings.37 It is documented that the majority
of isolates in the largest cohort of HIV-infected patients
presenting with S. aureus BSI were CA-MRSA (54%).
Moreover, CA-MRSA was associated with increased prob-
ability of endocarditis and increased risk of death com-
pared to other S. aureus strains.38 Studies suggested HIV-
infected patients to be at increased risk of CA-MRSA
because of overlapping community networks as well as the
high prevalence of intravenous drug use (IVDU). IVDU,
hemodialysis and CD4 cell count <200 cells/mL are inde-
pendent risk factors for CA-MRSA.39 Recent data from a
study by Kempkerr et al. suggest an association with
advanced age, black ethnicity and AIDS.40
Coagulase-negative staphylococci
In a recent European study reporting the results of a 10 y
survey of BSI in HIV-infected patients, coagulase-nega-
tive staphylococci were the principal isolated patho-
gens.41 In this study, among 54 episodes of sepsis, 26%
were caused by coagulase-negative staphylococci, 20% by
Streptococcus pneumoniae and 13% by Enterococcus spp.
The most frequent diagnoses in this group were cathe-
ter-related BSI and pneumonia. Prior AIDS diagnosis,
nadir of CD4 <200 cell/mL and a current CD4 cell count
<200 cell/mL were the risk factors. Notably, 56% of these
episodes were nosocomial. The 1 and 6 month mortality
were 17% and 28%, respectively.41 Moreover, the Spanish
single-hospital study mentioned above reported S. aureus
(10.7%) and coagulase-negative staphylococci (8.6%) as
the most frequent causative agents of 67 Gram-positive
BSI (36% of total BSI).34 Other studies report lower rates
of BSI due to coagulase-negative staphylococci, ranging
from 0%–6%.11,32,33,42
Gram-negative bacteria
Among the Gram-negative bacteria, nontyphoidal Sal-
monella (NTS) is correlated to HIV infection. NTS refers
to infections caused by all serotypes of Salmonella except
typhi and paratyphi A, B and C. NTS transmission can
occur via the consumption of food or water contami-
nated with animal feces and, less frequently, through
direct contact with infected animals and/or directly
between humans. Salmonella infection can have a wide
spectrum of clinical presentations: from a self-limiting
enterocolitis to a bacteremia with metastatic foci, involv-
ing bones, joints, liver, spleen and the meninges.43 From
the beginning of the HIV pandemic, an increased inci-
dence of NTS bacteremia in HIV-infected patients com-
pared to the general population, was described.44-46
Indeed, recurrent Salmonella bacteremia was included
among the AIDS-deﬁning conditions.14 Furthermore,
NTS bacteremia have high mortality and a tendency to
relapse in HIV-infected patients.47 A prospective study
conducted in Malawi in adult patients hospitalized for
NTS found that 99% of them were HIV-positive. The
inpatient mortality rate was 47%, and 43% of the survi-
vors had a recurrence.47 Nevertheless, the burden of NTS
bacteremia among AIDS-related opportunistic infections
has changed over time. Before the introduction of cART,
NTS were a major source of BSI and were associated
with increased mortality.48 After 1996, the incidence of
recurrent NTS bacteremia decreased signiﬁcantly among
patients who achieved favorable immune-virological
response after receiving cART. Hung et al. followed up
93 patients who received a diagnosis of NTS bacteremia
from June 1994 to June 2006 in Taiwan.49 They found
that patients who received cART had an incidence of
recurrent NTS bacteremia that was signiﬁcantly lower
compared to patients enrolled in the pre-cART era. In
particular, the incidence of recurrent NTS bacteremia
was 2.56 cases per 100 person-years in the cART era ver-
sus 70.56 cases per 100 person-years in the pre-cART era
(P < 0.001). Recurrent NTS bacteremia occurred mostly
in patients with a low CD4 cell counts in both the pre-
cART and the cART era (median CD4 cell count, 8 cells/
mL and 20 cells/mL, respectively).49 Nevertheless, this
epidemiologic trend in developed and developing coun-
tries is not homogenous. Studies in Africa found NTS is
the most frequent Gram-negative isolate, followed by
E. coli.4,50–52 A study in Tanzania showed a high preva-
lence (7.6%) of NTS bacteremia among febrile HIV adult
patients admitted at a tertiary hospital compared to non-
HIV patients (0.5%), proving NTS BSI to be a common
occurrence in this setting.52 A similar scenario was
observed in Asia.33,53,54 In a study of BSI in HIV-infected
persons in 2006–2008 in Southeast Asia, Varma et al.
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found NTS to be the most common bacterial cause of
BSI.53 Likewise, Kiertiburanakul et al. described the pat-
tern of BSI among HIV-infected patients in the cART
era in Thailand and found Gram-negative bacteria were
the ﬁrst cause of BSI (39.6%) and, among them, Salmo-
nella spp was the most frequent pathogen (15.6%).54
By contrast, E. coli and P. aeruginosa are the domi-
nant species among Gram-negative pathogens in Europe
and US, and there is a lower rate of Salmonella spp.
infections.11,30,33
Escherichia coli and pseudomonas aeruginosa
In the nosocomial setting, Gram-negative bacteria are a
minor source of BSI compared to Gram-positive.55,11,33
In a 12 months multicenter prospective study of patients
with advanced HIV infection, Petrosillo et al. found
Gram-negative organisms accounting for approximately
one-ﬁfth of all BSI and 12.9% of catheter-related BSI. E.
coli and P. aeruginosa were the most frequent Gram-neg-
ative isolates.55 Afessa et al. found that Gram-negative
bacteria caused 31% of nosocomial bacteremia in hospi-
talized HIV-infected patients, with P. aeruginosa as the
most common pathogen.11 Similarly, in a retrospective
study by Ortega et al., Gram-negative bacteria caused
31% of nosocomial BSI both in the pre-cART and in the
cART era. P. aeruginosa and E. coli were the most fre-
quently isolated microorganisms in these studies.33
Mycobacteria
The isolation of a mycobacterium from a blood culture rep-
resents amanifestation of disseminatedmycobacterial infec-
tion. It can be caused by both tubercular (MTB) and non-
tubercular (NTBM) mycobacteria and is typical of
immuno-compromised patients. In Western countries BSI
caused by mycobacteria are uncommon. Conversely, they
are frequent in limited resource settings, like some South-
East Asiatic and sub Saharan African countries, where
mycobacteria constitute a major cause of sepsis and account
for high percentages of positive blood cultures in HIV-
infected patients. A mycobacterial infection should be
always suspected in HIV-infected patients coming from
high prevalence countries. The mycobacteria account for a
number of BSI ranging from 17% to 54% of all etiologies in
studies performed in endemic areas (Table 1).42,50,53,56-58
This high prevalence may depend on the high frequency of
tubercular disease in these geographic areas, as nearly one
quarter of the new MTB cases worldwide are estimated to
occur in sub-Saharan Africa.59 In addition, advanced HIV
disease may play a role. In many countries, especially in
those with difﬁcult access to care, HIV infection is often
diagnosed in advanced stages, when the number of CD4 cell
is extremely low. In the above-mentioned studies, patients
diagnosed with mycobacterial BSI had a CD4 cell count
<100 cells/mL in most cases with a range of median values
between 15 and 129 cells/ mL.53,42,54 In this setting, myco-
bacterial BSI are relatively frequent, not only in cases of
overt BSI, but also when the symptoms are less severe, even
when pulmonary tuberculosis is considered improbable. In
a recent study performed in Malawi, all HIV-infected
patients with a CD4 cell count <250 cells/mL and with
chronic fever and/or weight loss, but negative smear for
mycobacteria, were investigated.56 Among 469 patients, 61
had a positive blood culture and mycobacteria accounted
for 24% of all isolated (11 cases of MTB and 4 NTBM). On
the other hand, MTB BSI may present as severe sepsis, in
which the differential diagnosis between bacterial and
mycobacterial origin is challenging. In a study performed in
Uganda, nearly 1 in 4 HIV-infected patients hospitalized
with severe sepsis had MTB bacteremia.42 In this study,
MTB was the commonest etiology of BSI (23.4% of cases),
while NTBM constituted 4% of isolates. Several attempts
have been made to outline the proﬁle of the typical patients
at risk for mycobacterial BSI. They are usually less likely to
receive cART,42 with signiﬁcantly lower median CD4 cell
counts,42,54,60 higher HIV RNA,54 fever and cough lasting
for > 1 month,60 weight loss of >10 %60 and presence of
lymphadenopathies.60 Moreover, they were more likely to
have community-acquired infections, were younger com-
pared to patients with bacterial BSI54 and their hemoglobin
values were below the median levels.56 Jacob et al. even pro-
posed a score based on male sex, increased heart rate, low
CD4 cell count, absence of cART, fever, low serum sodium
and low hemoglobin.42 Score higher than 21 points corre-
sponded to a probability of having a diagnosis of MTB bac-
teremia greater than 70% in the study, but the
characteristics considered were not speciﬁc, because many
of them are present in non-controlled HIV infection also in
absence of BSI. Thus, the possibility of such a diagnosis
must always be taken into account and cultures for myco-
bacteria should always be performed, regardless of scores,
especially in patients with low CD4 cell count or if there is
no response to antibiotic therapy. Themajority of mycobac-
teria infection are caused by TBM, but in patients with very
low CD4 cell count (<50 cells/ mL) atypical mycobacteria
are also possible and in particular organisms of the Myco-
bacterium avium complex (MAC).61 Likewise to TBM,
MAC BSI are associated with high plasma HIV-RNA levels,
but also with previous opportunistic infections and coloni-
zation of the respiratory or gastrointestinal tracts.61 The eti-
ological diagnosis is not possible until the result of cultures
become positive, but their median time of response exceeds
3 weeks, limiting their role for immediate clinical manage-
ment.62 The outcome of this kind of infection is poor, and
the tubercular etiology of BSI has been found to be a
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predictive factor of mortality itself in univariate logistic
regression among patients with sepsis.54 The 30-daymortal-
ity rate has been estimated higher than those seen in other
BSI inHIV-infected patients,42 with amortality rate of about
50% during the hospitalization.60,63
Fungi
In the cART era, consistent with the trend registered
for bacterial infections, fungal BSI decreased signiﬁ-
cantly compared to the pre-cART era (Table 1).34,64
They constitute a minority of BSI and are found
almost exclusively in patients with advanced HIV.
The predictive factors of fungal BSI are prior AIDS-
deﬁning illness, greater age, lower CD4 cell count and
high HIV-RNA.54,65 Different fungal species (includ-
ing Cryptococcus spp, Candida spp., Penicillium mar-
neffei and Histoplasma capsulatum) have been
isolated in HIV-infected patients, with higher mortal-
ity rates compared to non HIV-infected patients.54
Cryptococcosis is the most common life-threatening
systemic fungal infection and extrapulmonary crypto-
coccosis is an AIDS-deﬁning illness.14 It occurs typi-
cally in patients with low compliance with routine
medical care and with cART.66,67 In a French surveil-
lance study, 1644 cases of cryptococcosis in HIV-
infected patients were reviewed. The total number of
cases rose steadily until 1995, decreased sharply in
1996 and 1997, and reached a plateau thereafter.66 In
another 12 y study in a tertiary care hospital in Swit-
zerland, 315 patients were diagnosed with fungemia.
Among them, 12% were HIV-infected and 35% died
within 6 months after fungemia. Cryptococcus spp.
and Candida spp were the most frequently identiﬁed
species.64 In a retrospective cohort study in Thailand
in 2004–2008, data were collected for 140 HIV-
infected patients with BSI. Cryptococcus neoformans
was the pathogen isolated most frequently (20.8% of
cases). Other fungal pathogens, less frequently iso-
lated, were P. marneffei (2.7%) and H. capsulatum
(0.7%). Overall, a fungal etiology was proved in 35/
140 cases (25%).54 In the same study, 59% of patients
were in CDC clinical stage C and only 36% were on
cART. The predictive factors for fungal etiology were
older age, focal site infection, kidney insufﬁciency,
higher HIV-RNA and low CD4 cell count.54 Candide-
mia in the pre cART era was a common nosocomial
infection in HIV-infected patients hospitalized in
ICU, or those with hematological malignancies and
neutropenia.64,68 In a single-hospital study from 1990
to 1995 in France, the overall mortality was 38% in
13 episodes of candidemia, which was considered a
potentially lethal nosocomial complication during
late-stage AIDS.69 A retrospective case control study
in the cART era highlighted a signiﬁcant reduction in
the incidence of all cases of hospital-acquired candi-
demia compared to the pre cART era. By contrast,
the overall mortality rate was higher (59%).70 Despite
the use of cART, candidemia represents a severe com-
plication in advance-stage AIDS.70
P. marneffei and H. capsulatum fungemia are com-
mon only in the respective endemic areas (Asia and
South America) and they must be investigated as proba-
ble causative agents in people from those areas, including
travelers.31,64,71-74
Conclusions
BSI in HIV-infected patients have a wide spectrum of
possible etiologies, heavily inﬂuenced by the geographic
area and by the availability of cART. The clinical mani-
festations are similar to those of control patients; how-
ever, the incidence and mortality of BSI are often higher
in a HIV population. Higher HIV-RNA, low CD4 cell
count and an AIDS-deﬁning condition remain the pre-
dictive factors in this setting. Current guidelines recom-
mend the ‘test and treat’ strategy for all HIV-infected
people, independently of the CD4 cell count and the clin-
ical stage.75 Such an approach should result in an
increasing HIV population with good immunological
status, which will lead to a drop in AIDS-deﬁning condi-
tions. In this scenario, a reduction of BSI due to NTS,
Mycobacteria and Cryptococci can be expected. Total
disappearance of these conditions is hampered, however,
by the ‘late presenter’ issue. Indeed, too many patients
still have their HIV status diagnosed in an advanced
stage of disease, when their CD4 cell count is already
very low. Another factor that will probably have an
impact on the rate of BSI in HIV infected patients is the
fact that many of them have now the possibility to
become older, thus risking the typical problems of elderly
people, like cardiovascular disease, hypertension, diabe-
tes mellitus, chronic kidney disease, osteopenia/osteopo-
rosis and non-AIDS deﬁning cancers. These patients,
like their HIV-negative counterpart, are at risk of hospi-
talization and exposure to nosocomial infections; there-
fore, an increase of nosocomial BSI in HIV patients can
be expected. We expect BSI will always be a serious dis-
ease with a heavy burden in terms of morbidity and mor-
tality in HIV-infected patients; those with advanced
diseases and those in care from a long time and aging
with HIV infection represent the highest risk groups.
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